Glenmark Expects Cash Surge From License Deals in Next 18 MonthsBy
Diabetes business to grow 30 percent per year next three years
Open to transformational acquisition after three or four years
Glenmark Pharmaceuticals Ltd. expects a surge of new cash to hit its books in the next 18 months from licensing out its intellectual property as it seeks to transform from a maker of generic medicines to developing new ones.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.